Omega-3 PUFA in Prevention of Cardiovascular & Metabolic Diseases

Status Recruiting

Clinical Trial Summary

The study is aimed to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.

Clinical Trial Description

More than four million people in Europe (47%) and more than 1.9 million people in European Union (EU) (40%) die of cardiovascular diseases (CVD) every year. CVD mortality in EU is 43% in women and 36% in men. In Central and Eastern Europe, much more people die of CVD than in Western, Northern and Southern European countries. The World Health Organization (WHO) states that number of deaths in Slovakia is much higher than in Western European countries, even higher than in V4 countries - Slovakia, Czech Republic, Poland and Hungary

In the first stage of the project fatty acids will be analyzed with the focus on the ratio of omega-6 and omega-3 polyunsaturated fatty acids in fatty food for normal consumption and in nutritional supplements containing omega-3 polyunsaturated fatty acids.

In the second phase of the project risk factors of cardiovascular diseases for people without and people with a history of cardiovascular disease will be monitored and compared. There will be monitored and compared a wide range of laboratory markers of clinical biochemistry, immunology, pathological physiology in order to determine cardiovascular risk for men and women in different age categories.

The third stage will monitor the effect of natural plant and animal sources and pharmacological nutritional supplements with omega-3 polyunsaturated fatty acids on obesity, metabolic syndrome and cardiovascular risk factors.

The aim of this study is to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04208308
Study type	Interventional
Source	Pavol Jozef Safarik University
Contact	Zdenka Hertelyová, Dr. PhD.
Phone	+421552343225
Email	zdenka.hertelyova@upjs.sk
Status	Recruiting
Phase	Early Phase 1
Start date	January 15, 2013
Completion date	December 20, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04635202` - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome	N/A
Completed	`NCT05343858` - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome	N/A
Completed	`NCT04053686` - An Intervention to Reduce Prolonged Sitting in Police Staff	N/A
Active, not recruiting	`NCT05891834` - Study of INV-202 in Patients With Obesity and Metabolic Syndrome	Phase 2
Recruiting	`NCT05040958` - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed	`NCT03644524` - Heat Therapy and Cardiometabolic Health in Obese Women	N/A
Active, not recruiting	`NCT02500147` - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)	Phase 4
Recruiting	`NCT03227575` - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control	N/A
Recruiting	`NCT05972564` - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function	Phase 1/Phase 2
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Recruiting	`NCT05956886` - Sleep Chatbot Intervention for Emerging Black/African American Adults	N/A
Completed	`NCT06057896` - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting	`NCT03613740` - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion	Phase 2
Completed	`NCT04498455` - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency	Phase 4
Completed	`NCT05688917` - Green Coffee Effect on Metabolic Syndrome	N/A
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT03697382` - Effect of Daily Steps on Fat Metabolism	N/A
Completed	`NCT03241121` - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome	N/A
Completed	`NCT04509206` - Virtual Teaching Kitchen	N/A
Completed	`NCT05124847` - TREating Pediatric Obesity	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Omega-3 PUFA in Prevention of Cardiovascular and Metabolic Diseases (CARDMET3) — CARDMET3

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms